How to analyze the company?LEARNWhat should you know before buying?
Get a brief AI stock analysisSaves ~ 15 minutes of your time

RC

NYSE:RCUS
Get a brief AI stock analysisSaves ~ 15 minutes of your time

RC

Arcus Biosciences IncNYSE RCUS Stock Report

Get a brief AI stock analysis
Saves ~ 15 minutes of your time

Price

Market cap $B

Exchange

XNYS - New York Stock Exchange, Inc

FAIR VALUE

Is RCUS undervalued compared to its fair value?

The fair value of RCUS stock is hidden USD. Relative to the market price of 14.73 USD Arcus Biosciences Inc is hidden.

Arcus Biosciences, Inc. engages in the development and commercialization of immunotherapies. The company is headquartered in Hayward, California and currently employs 500 full-time employees. The company went IPO on 2018...[More about valuation]

Arcus Biosciences Fair Value

hidden
UNLOCK
What is fair value?

Market cap:

1.34 $B

Price:

14.73 USD

Fair value:

hidden

Max value:

hidden

Min value:

hidden

P/E:

hidden

EPS:

-0.046

FINANCIALS

Arcus Biosciences financial for reporting period

Income Statement

0.14 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
0.004 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
-0.004 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
Revenue analysis

0.14 B 100%
-0.004 B -3%

Balance Sheet

1.3 B
0.71 B

Financial Position Analysis

Assets

1.3 B
Current Assets
1.1 B
Total non-current assets
0.23 B

Total current liabilities
0.2 B
Total non-current liabilities
0.38 B

Cash Flow Statement

-0.006 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
-0.002 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A

Arcus Biosciences fundamental analysis for trailing twelve months (TTM)

Profitability Indicators


Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Solvency Indicators


Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Efficiency Indicators

-41 %

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%
-178 %

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%
-19 %

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Dupont Analysis

Stability Indicators

STOCK ANALYSIS

Is RCUS attractive for investment based on fundamental analysis?

RCUS stock rating is hidden. Arcus Biosciences is a hidden by Eyestock methodology.

Get RCUS Stock Rating
to complete you analysis
UNLOCK
Learn more about quality score?

Net Profit Margin:

-97

Gross Margin:

CFO / Debt ratio:

hidden

Current ratio:

4.9

Debt / Equity ratio:

ROE:

-41

ROIC:

hidden

Stability Ratio (2y):

hidden

Stability Ratio (5y):

hidden

Earnings quality:

hidden

RCUS analysis by AI

Eyebot AI analysis

We carefully consider 10 indicators for RCUS to calculate the final rating score. Use AI leverage to quickly get the main conclusions before diving into the details

Arcus Biosciences Inc competitors

AB

ABBV

Abbvie Inc

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. The company is headquartered in North Chicago, Ill...

Discover

AM

AMGN

Amgen Inc

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. The Company...

Discover

VR

VRTX

Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs fo...

Discover

Arcus Biosciences Inc dividends

RCUS dividend metrics

Payout ratio
Dividend yield
Annual dividend
Dividend streak
Average dividend yield over 3 years
Average dividend yield over 5 years

Dividend per share

By years
By payments
1y
3y
5y
All time
This ticker has no dividend history

About RCUS stock

About the company Arcus Biosciences Inc

Market cap $B

1.34

Dividend yield

Shares outstanding

73.0113 B

Arcus Biosciences, Inc. engages in the development and commercialization of immunotherapies. The company is headquartered in Hayward, California and currently employs 500 full-time employees. The company went IPO on 2018-03-15. The firm's six investigational products are in the clinical development, with its molecule, an anti-TIGIT antibody, which is in two phase III registrational studies. The firm's differentiated combination therapies are developing to treat multiple large tumor types, including lung, colorectal, prostate and pancreatic cancers. Its clinical development pipeline includes Domvanalimab, AB308, Etrumadenant, Quemliclustat, Zimberelimab and AB521. Domvanalimab is its Fc-silent anti-TIGIT monoclonal antibody. AB308 is its Fc-enabled anti-TIGIT monoclonal antibody. Etrumadenant is designed to inhibit the adenosine-driven impairment of tumor-infiltrating lymphocytes and myeloid cells (dendritic cells, macrophages), mediated by the A2a and A2b receptors. Quemliclustat is an extremely potent and selective small-molecule CD73 inhibitor. Zimberelimab is its anti-PD-1 antibody.

RCUS profile

  • Ticker

    RCUS

  • Country

    USA

  • Exchange

    XNYS - New York Stock Exchange, Inc

  • Report currency

    USD - US dollar

  • IPO date

    15 March 2018

  • Sector

    Healthсare

  • Industry

    Biotechnology

  • Employees

    500

  • City

    Hayward

  • Address

    3928 Point Eden Way

  • Cusip

    03969F109